Loading...
17 vitamin A COVID-19 controlled studies, 5 RCTs
https://c19early.org/vameta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Al-Sumiadai 86% 0.14 [0.03-0.61] death 2/70 14/70 Improvement, RR [CI] Treatment Control Al-Sumiadai 67% 0.33 [0.07-1.57] progression 2/50 6/50 Rohani (DB RCT) 26% 0.74 [0.31-1.76] hosp. 8/89 11/91 Rohani (DB RCT) 32% 0.68 [0.20-2.33] no recov. 4/89 6/91 Rohani (DB RCT) 80% 0.20 [0.05-0.91] no recov. 2/89 10/91 Rohani (DB RCT) 87% 0.13 [0.03-0.61] no recov. 1/89 8/91 Rohani (DB RCT) 49% 0.51 [0.13-1.98] no recov. 3/89 6/91 Rohani (DB RCT) 63% 0.37 [0.12-1.12] no recov. 4/89 11/91 Rohani (DB RCT) 20% 0.80 [0.31-2.04] no recov. 7/89 9/91 Rohani (DB RCT) 40% 0.60 [0.25-1.45] no recov. 7/89 12/91 Sarohan -282% 3.83 [1.58-9.24] death 9/10 4/17 Beigm.. (SB RCT) 89% 0.11 [0.01-1.98] death 0/30 4/30 ICU patients CT1 Beigm.. (SB RCT) 41% 0.59 [0.17-1.28] hosp. 4/30 16/30 ICU patients CT1 Beigm.. (SB RCT) 45% 0.55 [0.38-0.78] SOFA 30 (n) 30 (n) ICU patients CT1 Elkazzaz (RCT) 86% 0.14 [0.01-2.60] death 0/20 3/20 Elkazzaz (RCT) 67% 0.33 [0.08-1.46] ICU 2/20 6/20 Elkazzaz (RCT) 35% 0.65 [0.55-0.76] recov. time 20 (n) 20 (n) Elkazzaz (RCT) 44% 0.56 [0.48-0.65] viral time 20 (n) 20 (n) Somi (RCT) -50% 1.50 [0.29-7.73] death 3/15 2/15 Somi (RCT) 0% 1.00 [0.24-4.18] ventilation 3/15 3/15 Somi (RCT) 25% 0.75 [0.20-2.79] ICU 3/15 4/15 Somi (RCT) -76% 1.76 [0.73-4.26] no improv. 15 (n) 15 (n) Somi (RCT) -8% 1.08 [0.87-1.34] hosp. time 15 (n) 15 (n) Doocy 26% 0.74 [0.11-4.80] death 1/8 23/136 Chung (RCT) 75% 0.25 [0.06-0.99] PASC 9 (n) 8 (n) LONG COVID Chung (RCT) 68% 0.32 [0.01-6.90] PASC 0/9 1/8 LONG COVID Chung (RCT) 70% 0.30 [0.04-2.31] PASC 1/9 3/8 LONG COVID Chung (RCT) 75% 0.25 [0.07-0.89] PASC 2/9 7/8 LONG COVID Al-Sumiadai 64% 0.36 [0.23-0.54] cases 20/97 65/112 COVIDENCE UK Holt 56% 0.44 [0.06-2.96] cases 1/91 445/15,136 Nimer 21% 0.79 [0.45-1.35] hosp. 15/144 204/2,004 Nimer 21% 0.79 [0.46-1.30] severe case 17/144 243/2,004 Vaisi 17% 0.83 [0.48-1.00] hosp. 1,140 (n) 2,815 (n) Vaisi 11% 0.89 [0.69-0.98] symp. case 1,140 (n) 2,815 (n) Vitamin A COVID-19 outcomes c19 early1 CT: study uses combined treatment Favors vitamin A Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit
